Is warfarin-related fetal risk dose dependent? Vitale et al. (12) in 1999 suggested a close relationship between warfarin dosage and fetal complications in pregnant women with MPHV. These investigators studied 58 pregnancies and showed that the majority of fetal complications were related to warfarin dose of Ͼ5 mg per day. Thirty-three gestations in women taking Յ5 mg were associated with 28 healthy babies (82%) in comparison to 22 fetal complications (fetal loss 76%, warfarin embryopathy 8%) in 25 women treated with Ͼ5 mg daily. The same group of investigators (11) later reported poor outcome in 30 of 71 pregnancies (fetal loss in 28 cases, and embryopathy in 2 cases). Multivariable analysis identified warfarin at daily dose Ͼ5 mg as a significant predictor (p Ͻ 0.001) of poor fetal outcome. This information resulted in a recommendation to consider the use of oral anticoagulation throughout pregnancy when warfarin dose is Ͻ5 mg daily by the recently published European Society of Cardiology guidelines (14) for the management of women with heart disease in pregnancy.
In this issue of the Journal, De Santo et al. (15) report additional 16 pregnancies in women who received therapeutic anticoagulation with a daily warfarin dose Ͻ5 mg before an aortic valve replacement and later received a newgeneration MPHV. These patients, who continued to receive low-dose warfarin throughout pregnancy with very close follow-up, had no thromboembolic or hemorrhagic complications, and all had healthy babies. Patients were carefully monitored with weekly international normalized ratio (INR) determinations targeted by the investigators to be between 1.5 and 2.5.
Although these results are encouraging, they suffer from important limitations and, therefore, can have only limited clinical impact at the present time. The findings can be applied only to patients with new-generation aortic MPHV adequately anticoagulated with low-dose oral anticoagulation. In addition, as indicated by the investigators, the combined number of patients included in their 3 publications (11, 12, 15 ) is small and cannot be considered conclusive. A further concern is that, in spite of the absolute safety reported in the study by De Santo et al. (15), the results are not supported by other publications describing fetal complications with low-dose warfarin. Sadler et al. (10) reported 7 miscarriages in 11 women treated with Ͻ5 mg warfarin daily compared to 5 miscarriages in 11 women treated with Ͼ5 mg daily. Shannon et al. (9) reported spontaneous abortion in 8 of 10 women receiving warfarin during the first trimester; 6 of these were treated with Յ5 mg per day and the other 2 received 6 mg. In addition, 1 case of warfarin embryopathy was associated with a warfarin dose of 5 to 6 mg per day. McLintock et al. (16) reported 2 perinatal deaths and 2 stillbirths as a result of fetal intracerebral hemorrhage in women taking warfarin at daily doses of 4 mg and 5 mg, respectively, and an infant death due to warfarin embryopathy in a woman taking 6 mg per day until week 34. Mehndiratta et al. (13) reported a case of severe growth retardation and warfarin embryopathy in a patient treated with warfarin 3 mg per day throughout pregnancy.
De Santo et al. (15) used a relatively low INR goal between 1.5 and 2.5 on the basis of recent studies showing a low incidence of thromboembolic events among nonpregnant patients with new-generation MPHV (17, 18) . Because pregnant patients were not included in these studies, the safety of this approach for pregnancy remains unproven. For this reason, and until more data are available, it seems advisable to follow the American College of Cardiology/ American Heart Association guidelines (19) and use a warfarin dose during pregnancy aiming to achieve an INR level of Ն2.5 even in patients with new-generation MPHV in the aortic position.
Another limitation associated with the protocol presented by De Santo et al. (15) is a mandatory cesarean section delivery in all patients. Although relatively safe, a cesarean delivery is associated with a substantial increase in shortand long-term risks, including surgery-related infections, bleeding, thromboembolism, pain, and damage to pelvic organs, and later, increased risk of miscarriage, ectopic gestation, placenta previa, and placenta accreta (20) .
Because of the remaining concern regarding fetal effects of warfarin, recent guidelines recommendations to use lowdose warfarin, if therapeutically effective, throughout pregnancy (14) seem premature and require further validation.
The only patient reported by De Santo et al. (15) to have valve thrombosis was treated with low-molecular-weight heparin at a dose titrated to achieve peak anti-Xa levels of 0.7 to 1.2 IU/ml, as recommended by recent guidelines (14, 19) . These guidelines, however, ignore the manufacturer recommendations to monitor both peak and trough levels (21) . The importance of measuring trough levels was first demonstrated by Barbour et al. (22) , who evaluated 138 peak and 112 trough anti-Xa levels in 13 pregnancies and found only 9% of trough levels at Ͼ0.5 IU/ml. Even when peak levels were between 0.75 IU/ml and 1.0 IU/ml, only 15% of trough levels were Ͼ0.5 IU/ml. These findings were later confirmed by Friedrich and Hameed (23) , who studied 15 pregnant subjects receiving therapeutic doses of enoxaparin given twice daily. While all peak levels at 3 to 4 h were between 0.5 IU/ml and 1.0 IU/ml, 20% at 8 h and 73% at 12 h were subtherapeutic. The relationship between 177 paired peak and trough levels of anti-Xa during pregnancy were further studied by our group (24); in 26 pregnant patients receiving adjusted-dose enoxaparin given every 12 h, peak levels of 0.7 to 1.2 IU/ml were associated with subtherapeutic trough level (Ͻ0.6 IU/ml) in Ͼ50% of the cases, and only 7 (6%) determinations, 6 of them with trough levels Ͼ0.8 IU/ml, had peak levels Ͼ1.5 IU/ml. These data, in addition to documented risk of valve thrombosis with subtherapeutic pre-dose anti-Xa levels (2), support the importance of routine measurement and maintenance of trough levels at therapeutic range in pregnant women with MPHV (Ն0.6 IU/ml in lower risk women, and Ն0.7 IU/ml in high-risk women) ( Table 1) (25) . Peak levels should also be monitored to detect excessive anticoagulation (i.e., anti-Xa Ͼ1.5 IU/ml), which requires switching to 8-hourly dosing.
Our Recommended Approach to Anticoagulation Therapy for Women With MPHV During Pregnancy Warfarin (INR 2.5 to 3.5) for 35 to 36 weeks followed by IV UFH (aPTT Ͼ2.5) to parturition ϩ ASA 81 to 100 mg/day LMWH SQ Q12 h (trough anti-Xa Ն0.6 IU/ml, peak anti-Xa Ͻ1.5 IU/ml) to 35 to 36 weeks, then UFH IV (aPTT Ͼ2.0) to parturition OR OR LMWH SQ Q12 h (trough anti-Xa Ն0.7 IU/ml, peak anti-Xa Ͻ1.5 IU/ml) or UFH SQ Q12 h or IV* (mid interval aPTT Ͼ2.5) for 12 weeks, followed by warfarin (INR: 2.5 to 3.5) to 35 to 36 weeks, then UFH IV (aPTT Ͼ2.5) to parturition ϩ ASA 81 to 100 mg/day.
LMWH SQ Q12 h (trough anti-Xa Ն0.6 IU/ml, peak anti-Xa Ͻ1.5 IU/ml) or UFH SQ Q12 h or IV* (mid interval aPTT Ͼ2.0) for 12 weeks followed by warfarin (INR: 2.5 to 3.0) until 35 to 36 weeks, then UFH IV (aPTT Ͼ2.0) to parturition *IV preffered. aPTT ϭ activated partial thromboplastin time; ASA ϭ acetylsalicylic acid; INR ϭ international normalized ratio; IV ϭ intravenous; LMWH ϭ low-molecular-weight heparin; MPHV ϭ mechanical prosthetic heart valve; Q ϭ every; SQ ϭ subcutaneous; TE ϭ thromboembolism; UFH ϭ unfractionated heparin.
